CTOs on the Move

Aerovate Therapeutics

www.aerovatetx.com

 
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aerovate Therapeutics raised $72.6M on 08/06/2020

Similar Companies

Bonna-Agela Technologies

Bonna-Agela Technologies is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MiRagen

miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.

Nurse On Call

Nurse On Call is a Naples, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CAMP4 Therapeutics

What if we told you that our bodies make use of only a few hundred different signaling pathways to control all of our 20,000 or so genes. We call it the gene circuitry code, unique for every gene in our body. CAMP4 has built a proprietary 4-D Gene Circuity Platform to codify the discrete set of combinatorial rules used by any human cell type central to disease pathology. By applying the power of computational biology and machine learning algorithms, CAMP4 is able to rapidly solve for druggable targets to control the output of any disease gene of interest.

Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices.